Skip to main content
Log in

The assessment of the economic return from controlled clinical trials

A framework applied to clinical trials of colorectal cancer follow-up

  • Original Papers
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Clinical trials can be considered health interventions as their primary aim is to impact on the health of a population. Given that resources are scarce for both health care and health related research, trials could be designed such that they can be demonstrated to be cost-effective, i.e., the costs of conducting the trial are justified given the forecasted long-term benefits.We demonstrate how a model can be used to predict the cost-effectiveness of undertaking a clinical trial comparing alternative regimens of colorectal cancer follow-up.The model forecasts costs and survival under two scenarios,with and without conducting a clinical trial, with the outcome assessed in terms of years to payback for the clinical trial.The methodology shown can be used both to provide information on appropriate trial design and/or in prioritizing between potential trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Douglas Coyle Clinical Epidemiology Unit, Ottawa Health Research Institute, 1053 Carling Avenue,Ottawa Hospital,Ottawa, Ontario K1Y 4E9,Canada, e-mail: dcoyle@ohri.ca

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coyle, D., Grunfeld, E. & Wells, G. The assessment of the economic return from controlled clinical trials . Eur J Health Econom 4, 6–11 (2003). https://doi.org/10.1007/s10198-002-0142-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-002-0142-5

Navigation